Login to Your Account

Clinic Roundup

Friday, October 11, 2013
• Genmab A/S, of Copenhagen, Denmark, reported top-line results from a Phase II study of the subcutaneous formulation of ofatumumab in relapsing-remitting multiple sclerosis (RRMS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription